References
- Naming the coronavirus disease (COVID-19) and the virus that causes it; [cited 2020 Aug 31]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
- Zhang N, Li C, Hu Y, et al. Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes Infect. 2020;22(6–7):231–235.
- Coronavirus (COVID-19) events as they happen; [cited 2020 May 27]. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.
- WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard ; [cited 2020 Sep 2]. Available from:https://covid19.who.int/?gclid=Cj0KCQjwhb36BRCfARIsAKcXh6FkNtoBrhYUpI0WAjhgROPBDc2EBbcY7cybJQKI9ppmV6s8n90iMRkaAqeNEALw_wcB.
- Worldometer. Coronavirus Cases. Worldometer. 2020, [cited 2020 Sep 2]:[1–22 p.]. Available from: https://www.worldometers.info/coronavirus/?.
- Symptoms of Coronavirus | CDC; [cited 2020 May 28]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
- Ahmed SF, Quadeer AA, McKay MR. preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12(3):254.
- Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of Coronaviruses. Trends Microbiol. 2016;24(6):490–502.
- Lan J, Ge J, Yu J, et al. Crystal structure of the 2019-NCoV spike receptor-binding domain bound with the ACE2 receptor 2 3. bioRxiv. 2020. doi:10.1101/2020.02.19.956235
- Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-NCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
- Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580(7805):576–577.
- Draft landscape of COVID-19 candidate vaccines; [cited 2020 Aug 30]. Available from: https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines.
- Protein vaccines – Latest research and news | Nature; [cited 2020 May 19]. Available from: https://www.nature.com/subjects/protein-vaccines.
- Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci. 2016;7(2):842–854.
- Tse LV, Meganck RM, Graham RL, et al. The current and future state of vaccines, antivirals and gene therapies against emerging Coronaviruses. Front Microbiol. 2020;11(April):658.
- Kar T, Narsaria U, Basak S, et al. A candidate multi-epitope vaccine against SARS-CoV-2. Sci Rep. 2020;10(1):10895.
- Abdelmageed MI, Abdelmoneim AH, Mustafa MI, et al. Design of multi epitope-based peptide vaccine against e protein of human 2019-ncov: an immunoinformatics approach. bioRxiv. 2020. doi:10.1101/2020.02.04.934232
- COVID-19 vaccine development pipeline; [cited 2020 May 23]. Available from: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/.
- Evaluation of the safety and immunogenicity of a SARS-CoV-2 rS (COVID-19) nanoparticle vaccine with/without matrix-M adjuvant – Full Text View – ClinicalTrials.gov; [cited 2020 Oct 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04368988?term=vaccine&recrs=a&cond=covid-19&draw=2.
- Ongoing Trials for Novel Vaccines in the prevention of COVID-19. 2020; [cited 2020 Aug 31]. Available from: https://cadth.ca/sites/default/files/covid-19/hc0004-0004-novel-vaccines-and-covid.pdf.
- Clinical study of recombinant Novel Coronavirus vaccine – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04466085?term=NCT04466085&draw=2&rank=1.
- Phase I clinical study of recombinant Novel Coronavirus Vaccine – Full Text View-ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04445194?term=longcom&draw=2.
- KBP-201 COVID-19 Vaccine trial in healthy volunteers – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04473690?term=vaccine&cond=covid-19&draw=3.
- SCB-2019 as COVID-19 Vaccine – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04405908?term=clover&cond=covid-19&draw=2&rank=1.
- Monovalent recombinant COVID19 vaccine – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04453852?term=vaccine&cond=covid-19&draw=5.
- ANZCTR – Registration; [cited 2020 Aug 31]. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true.
- A Phase I, prospective, open-labeled study to evaluate the safety and immunogenicity of MVC-COV1901 – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04487210?term=vaccine&cond=covid-19&draw=7.
- Safety, Tolerability and Immunogenicinity of a Coronavirus-like particle COVID-19 Vaccine in adults aged 18–55 Years. – Full Text View – ClinicalTrials.gov; [cited 2020 May 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT04450004.
- Dose-confirmation study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 COVID-19 vaccine in adults aged 18 years and older – Tabular View – ClinicalTrials.gov; [cited 2020 May 29]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04405076.
- Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19) – Full Text View – ClinicalTrials.gov; [cited 2020 May 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04283461?term=vaccine&cond=covid-19&draw=2.
- A study to evaluate efficacy, safety, and immunogenicity of mRNA-1273 vaccine in adults aged 18 years and older to prevent COVID-19 – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04470427?term=vaccine&cond=covid-19&draw=5.
- Jackson LA, Anderson EJ, Rouphael NG, et al. An MRNA Vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020. doi:10.1056/NEJMoa2022483
- Study to describe the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy adults – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 29]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04368728.
- Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study of COVID-19 RNA Vaccine BNT162b1 in adults. Nature. 2020;586:589–593.
- A study to evaluate the safety, reactogenicity and immunogenicity of vaccine CVnCoV in healthy adults – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT04449276.
- A dose-confirmation study to evaluate the safety, reactogenicity and immunogenicity of Vaccine CVnCoV in healthy adults – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04515147?term=vaccine&cond=covid-19&draw=11.
- Ascending dose study of investigational SARS-CoV-2 vaccine ARCT-021 in healthy adult subjects – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT04480957.
- ISRCTN – ISRCTN17072692: Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women; [cited 2020 Sep 31]. Available from: http://www.isrctn.com/ISRCTN17072692.
- Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers – full text view – ClinicalTrials.gov; [cited 2020 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04336410?term=ino+4800&draw=2&rank=1.
- Safety, tolerability and immunogenicity of INO-4800 followed by electroporation in healthy volunteers for COVID19 – Full Text View – ClinicalTrials.gov; [cited 2020 Sep 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04447781.
- Study of COVID-19 DNA Vaccine (AG0301-COVID19) – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04463472?term=NCT04463472&draw=2&rank=1.
- Safety and immunogenicity study of GX-19, a COVID-19 preventive DNA vaccine in healthy adults – Full Text View – ClinicalTrials.gov; [cited 2020 Sep 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04445389?term=vaccine&cond=covid-19&draw=3.
- Clinical trial of efficacy and safety of Sinovac’s adsorbed COVID-19 (inactivated) vaccine in healthcare professionals – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 26]. Available from:https://clinicaltrials.gov/ct2/show/NCT04456595.
- Safety and immunogenicity study of inactivated vaccine for prevention of SARS-CoV-2 infection (COVID-19) – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04383574.
- Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 infection (COVID-19) – Full Text View – ClinicalTrials.gov; [cited 2020 Sep 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04352608.
- Chinese Clinical Trial Register (ChiCTR); [cited 2020 May 27]. Available from: http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000031809.
- Chinese Clinical Trial Register (ChiCTR); [cited 2020 Sep 2]. Available from: http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000032459.
- Safety and immunogenicity study of an inactivated SARS-CoV-2 vaccine for preventing against COVID-19 in people aged ⩾60 years – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 28]. Available from:https://clinicaltrials.gov/ct2/show/NCT04470609?term=vaccine&cond=covid-19&draw=2.
- Safety and immunogenicity study of an inactivated SARS-CoV-2 Vaccine for preventing against COVID-19 – Full Text View – ClinicalTrials.gov; [cited 2020 Sep 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04412538?term=vaccine&cond=covid-19&draw=2.
- Whole-Virion inactivated SARS-CoV-2 vaccine (BBV152) for COVID-19 in healthy volunteers – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04471519.
- Phase III double-blind, Placebo-controlled Study of AZD1222 for the prevention of COVID-19 in adults – Full Text View; [cited 2020 Sep 1]. Available from: ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04516746.
- A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector); [cited 2020 Sep 2]. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=52006.
- A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector); [cited 2020 Sep 2]. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=51154.
- A study of Ad26.COV2.S in adults – Full Text View – ClinicalTrials.gov; [cited 2020 Sep 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04436276?term=NCT04436276&draw=2&rank=1.
- Clinical trial to evaluate the safety and immunogenicitiy of the COVID-19 vaccine (COVID-19-101); [cited 2020 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04497298.
- Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines. N Biotechnol. 2017;39(Pt B):174–180.
- Quan F-SS, Basak S, Chu K-BB, et al. Progress in the development of virus-like particle vaccines against respiratory viruses. Expert Rev Vaccines. 2020;19(1):11–24.
- Zha L, Zhao H, Mohsen MO, et al. Development of a vaccine against the newly emerging COVID-19 virus based on the receptor binding domain displayed on virus-like particles. - bioRxiv. 2020. doi:10.1101/2020.05.06.079830
- Medicago announces production of a viable vaccine candidate for COVID-19 | BioSpace; [cited 2020 May 24]. Available from: https://www.biospace.com/article/releases/medicago-announces-production-of-a-viable-vaccine-candidate-for-covid-19/.
- Medicago announces positive results in animal trials for its vaccine candidate against COVID-19 | Business Wire; [cited 2020 May 24]. Available from: https://www.businesswire.com/news/home/20200514005745/en/Medicago-Announces-Positive-Results-Animal-Trials-Vaccine.
- VBI vaccines announces collaboration with the National Research Council of Canada to develop pan-Coronavirus vaccine candidate targeting COVID-19, SARS, and MERS; [cited 2020 May 25]. Available from: https://www.businesswire.com/news/home/20200331005198/en/VBI-Vaccines-Announces-Collaboration-National-Research-Council.
- Rauch S, Jasny E, Schmidt KE, et al. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9(SEP):1963.
- Ology Bioservices, Inovio partner to manufacture COVID-19 DNA Vaccine with $11.9 million department of defense Grant | Ology Bioservices; [cited 2020 May 25]. Available from: https://www.ologybio.com/ology-bioservices-inovio-partner-to-manufacture-covid-19-dna-vaccine-with-11-9-million-department-of-defense-grant/.
- Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601.
- INOVIO. INOVIO’s COVID-19 DNA Vaccine INO-4800 demonstrates robust neutralizing antibody and T cell immune responses in preclinical models; 2020.
- Applied DNA Ships COVID-19 LinearDNATM Vaccine Candidates to Italian development partner to begin preclinical animal testing; [cited 2020 May 26]. Available from: https://www.businesswire.com/news/home/20200415005314/en/Applied-DNA-Ships-COVID-19-LinearDNATM-Vaccine-Candidates.
- Applied DNA and Takis Biotech Announce the production of neutralizing antibodies against SARS-CoV-2 After DNA vaccination in animals | Business Wire; [cited 2020 May 26]. Available from: https://www.businesswire.com/news/home/20200504005224/en/Applied-DNA-Takis-Biotech-Announce-Production-Neutralizing.
- Applied DNA and Takis Biotech expand COVID-19 vaccine development program to include 5th candidate | Business Wire; [cited 2020 May 26]. Available from: https://www.businesswire.com/news/home/20200402005451/en/Applied-DNA-Takis-Biotech-Expand-COVID-19-Vaccine.
- Immunomic therapeutics forms collaboration with EpiVax and PharmaJet to develop novel vaccine candidate against COVID-19 using its investigational UNITE platform | Business Wire; [cited 2020 May 26]. Available from: https://www.businesswire.com/news/home/20200409005696/en/Immunomic-Therapeutics-Forms-Collaboration-EpiVax-PharmaJet-Develop.
- COVID-19; [cited 2020 May 25]. Available from: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/.
- Zydus Cadila’s Covid-19 vaccine enters Phase II testing; [cited 2020 May 27]. Available from: https://www.clinicaltrialsarena.com/news/zydus-covid-vaccine-phaseii/.
- Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus | Business Wire; [cited 2020 May 26]. Available from: https://www.businesswire.com/news/home/20200416005985/en/Moderna-Announces-Award-U.S.-Government-Agency-BARDA.
- Moderna’s Work on a COVID-19 Vaccine Candidate | Moderna, Inc.; [cited 2020 May 26]. Available from: https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19.
- Moderna. Moderna announces positive interim phase 1 data for its MRNA vaccine (MRNA-1273) against Novel Coronavirus; 2020.
- Kaiser Permanente Washington Health Research Institute. Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) to prevent SARS-CoV-2 infection – full text view; [cited 2020 May 26]. Available from: ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04283461.
- COVE study: participate to make a world of difference | Moderna, Inc.; [cited 2020 May 29]. Available from: https://www.modernatx.com/cove-study.
- Arcturus therapeutics and catalent announce partnership to manufacture mRNA-based COVID-19 Vaccine Nasdaq:ARCT; [cited 2020 May 26]. Available from: https://www.globenewswire.com/newsrelease/2020/05/04/2026754/0/en/Arcturus-Therapeutics-and-Catalent-Announce-Partnership-to-Manufacture-mRNA-Based-COVID-19-Vaccine.html.
- Arcturus therapeutics announces that it has initiated dosing of its COVID-19 STARRTM MRNA vaccine candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 Study; 2020.
- CureVac’s optimized mRNA platform provides positive pre-clinical results at low dose for Coronavirus Vaccine Candidate; [cited 2020 Aug 26]. Available from: https://www.accesswire.com/589869/CureVacs-Optimized-mRNA-Platform-Provides-Positive-Pre-Clinical-Results-at-Low-Dose-for-Coronavirus-Vaccine-Candidate%0D.
- Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program | Pfizer; [cited 2020 Aug 26]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_dose_first_participants_in_the_u_s_as_part_of_global_covid_19_mrna_vaccine_development_program.
- BioNTech announces first quarter 2020 financial results and corporate progress; 2020.
- Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 Vaccine Development | Pfizer; [cited 2020 May 26]. Available from: https://www.businesswire.com/news/home/20200409005405/en/Pfizer-BioNTech-Announce-Details-Collaboration-Accelerate-Global.
- Press Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations – EpiVax, Inc. – informatics and immunology; [cited 2020 Aug 26]. Available from: https://epivax.com/news/press-release-etherna-consortium-cov-2-mrna-vaccine-for-high-risk-populations.
- Ziphius therapeutics announces acceleration of MRNA based vaccine development for COVID-19; 2020.
- Payne S. Viral vaccines. In Viruses. London: Elsevier; 2017. p. 73–79.
- Anti-viral strategies; [cited 2020 Aug 31]. Available from:https://msu.edu/course/mmg/569/vaccines.htm.
- A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety and immunogenicity of SARS-Cov-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia; [cited 2020 Aug 26]. Available from:https://www.ina-registry.org/index.php?act=registry_trial_detail&code_trial=16202009080721WXFM0YX.
- Laskar P, Yallapu MM, Chauhan SC. “Tomorrow never dies”: recent advances in diagnosis, treatment, and prevention modalities against Coronavirus (COVID-19) amid controversies. Diseases. 2020;8(3):30.
- Randomized, Blind, Placebo-controlled I/II Phase QAZCOVID-IN®- COVID-19 Inactivated Vaccine – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT04530357.
- Dynavax announces first quarter 2020 financial results | Dynavax Technologies Corporation; [cited 2020 May 28]. Available from: http://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-first-quarter-2020-financial-results.
- Valneva and dynavax collaborate to develop COVID-19 vaccine | 2020 April 24 | FDAnews; [cited 2020 May 22]. Available from: https://www.fdanews.com/articles/196792-valneva-and-dynavax-collaborate-to-develop-covid-19-vaccine.
- Kazakhstan starts preclinical trial of inactivated coronavirus vaccine; [cited 2020 May 22]. Available from:https://www.inform.kz/en/kazakhstan-starts-preclinical-trial-of-inactivated-coronavirus-vaccine_a3651033.
- WHO approves Kazakh COVID-19 vaccine for preclinical trials – The Astana Times; [cited 2020 May 22]. Available from: https://astanatimes.com/2020/05/who-approves-kazakh-covid-19-vaccine-for-preclinical-trials/.
- Goh GK-M, Dunker AK, Foster JA, et al. Shell disorder analysis suggests that pangolins offered a window for a silent spread of an attenuated SARS-CoV-2 precursor among humans. J. Proteome Res. 2020. doi:10.1021/acs.jproteome.0c00460
- Serum Institute ties up with US biotech firm to develop vaccine against COVID-19 | Cities News, The Indian Express; [cited 2020 May 21]. Available from: https://indianexpress.com/article/cities/pune/serum-institute-ties-up-with-us-biotech-firm-to-develop-vaccine-against-covid-19-6275051/.
- CodaVax-COVID for SARS-CoV-2 (COVID-19); [cited 2020 Aug 28]. Available from: https://codagenix.com/vaccine-programs/covid-19/.
- Griffith University researchers on the road to COVID-19 vaccine; [cited 2020 May 26]. Available from: https://news.griffith.edu.au/2020/04/23/griffith-university-researchers-on-the-road-to-covid-19-vaccine/.
- Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2(3):624–641.
- CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine; [cited 2020 May 26]. Available from: https://www.pasteur.fr/en/press-area/press-documents/cepi-collaborates-institut-pasteur-consortium-develop-covid-19-vaccine.
- Zydus Cadila launches a fast tracked programme to develop vaccine for the Novel Coronavirus, 2019-NCoV (COVID-19); [cited 2020 May 26]. Available from: https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf.
- SARS-CoV-2: DZIF scientists and the development of vaccines | German Center for Infection Research; [cited 2020 May 25]. Available from: https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines.
- Southern research, tonix team to develop potential vaccine against New Coronavirus; [cited 2020 May 21]. Available from: https://southernresearch.org/news/southern-research-tonix-team-to-develop-potential-vaccine-against-new-coronavirus/.
- TNX-1800 (Coronavirus Vaccine): Tonix Pharmaceuticals Holding Corp. (TNXP) ; [cited 2020 May 26]. Available from: https://www.tonixpharma.com/pipeline/tnx-1800-coronavirus-vaccine.
- IAVI and Batavia Biosciences Announce Collaboration – IAVI; [cited 2020 May 26]. Available from: https://www.iavi.org/newsroom/press-releases/2020/iavi-and-batavia-announce-collaboration-vsv-vector-epidemic-preparedness-vaccines.
- HKU State Key Laboratory for Emerging Infectious Diseases joins global effort to develop COVID-19 vaccine – Press Releases – Media – HKU; [cited 2020 May 25]. Available from: https://www.hku.hk/press/press-releases/detail/20788.html.
- UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine; [cited 2020 May 21]. Available from: https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/.
- Aurobindo Pharma expects Phase I and II trials of COVID-19 vaccine by end of 2020 – Express Pharma; [cited 2020 May 28]. Available from: https://www.expresspharma.in/covid19-updates/aurobindo-pharma-expects-phase-i-and-ii-trials-of-covid-19-vaccine-by-end-of-2020/.
- Yahalom-Ronen Y, Tamir H, Melamed S, et al. A single dose of recombinant VSV-ΔG-Spike vaccine provides protection against SARS-CoV-2 challenge. bioRxiv. 2020. doi:10.1101/2020.06.18.160655
- Choi Y, Chang J. Viral vectors for vaccine applications. Clin Exp Vaccine Res. 2013;2(2):97–105.
- Doremalen N, van Lambe T, Spencer A, Belij-Rammerstorfer , et al. J. ChAdOx1 NCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. 2020. doi:10.1101/2020.05.13.093195
- ISRCTN. A phase III study to investigate a vaccine against COVID-19: ISRCTN – ISRCTN89951424; [cited 2020 Aug 26]. Available from: http://www.isrctn.com/ISRCTN89951424.
- Phase III trial of A COVID-19 vaccine in adults 18 years of age and older – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT04526990.
- China’s CanSino pushes coronavirus vaccine into clinical testing as Moderna kicks off trial | FiercePharma; [cited 2020 May 21]. Available from: https://www.fiercepharma.com/vaccines/china-s-cansino-pushes-coronavirus-vaccine-into-clinical-testing-as-moderna-doses-1st.
- A study of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adult participants (ENSEMBLE); [cited 2020 Aug 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04505722.
- Clinical Trial of efficacy, safety, and immunogenicity of Gam-COVID-Vac vaccine against COVID-19 – Full Text View – ClinicalTrials.gov; [cited 2020 Aug 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&cond=covid-19&draw=3.
- ReiThera’s COVID-19 vaccine candidate enters phase 1 clinical study with first healthy volunteer dosed in Italy; [cited 2020 Aug 26]. Available from: https://www.reithera.com/wp-content/uploads/2020/08/reithera-fih-trial-pr-final.pdf.
- GeoVax progresses in Coronavirus (COVID-19) vaccine development program – GeoVax, Inc.; [cited 2020 May 21]. Available from: https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program.
- Update on Coronavirus (COVID-19) vaccine development program – GeoVax, Inc; [cited 2020 May 21]. Available from: https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program.
- Researchers from the Clínic-IDIBAPS receive about 2.4 million euros from the ISCIII for the fight against the coronavirus; [cited 2020 Aug 27]. Available from: https://www.clinicbarcelona.org/noticias/investigadores-del-clinic-idibaps-reciben-cerca-de-2-4-millones-de-euros-del-isciii-para-la-lucha-contra-el-coronavirus.
- Altimmune and the University of Alabama at birmingham to collaborate on development of single-dose, intranasal COVID-19 Vaccine – Altimmune; [cited 2020 Aug 21]. Available from: https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate.
- Altimmune completes first development milestone toward a single-dose intranasal COVID-19 Vaccine – Altimmune; [cited 2020 Aug 25]. Available from: https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single.
- Stabilitech’s COVID-19 Vaccine intended to be delivered in a disruptive thermally stable oral capsule | Home; [cited 2020 May 25]. Available from: https://www.stabilitech.com/stabilitechs-covid-19-vaccine-intended-to-be-delivered-in-a-disruptive-thermally-stable-oral-capsule/.
- Valo therapeutics to support development of a pan – Coronavirus Vaccine | Valo Therapeutics LTD; [cited 2020 Aug 25]. Available from: https://www.valotx.com/article/valo-therapeutics-support-development-pan-coronavirus-vaccine.
- Massachusetts Eye and Ear and Massachusetts General Hospital advancing novel experimental gene-based COVID-19 Vaccine, AAVCOVID; [cited 2020 Aug 27]. Available from: https://masseyeandear.org/news/press-releases/2020/05/mee-and-mgh-advancing-aavcovid-vaccine.
- Vaxart announces selection of its Oral COVID-19 vaccine lead Candidate | Vaxart; [cited 2020 May 25]. Available from: https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-selection-its-oral-covid-19-vaccine-lead.
- Li K, Li Z, Wohlford-Lenane C, et al. Single-dose, intranasal immunization with recombinant parainfluenza virus 5 expressing middle east respiratory syndrome Coronavirus (Mers-Cov) Spike protein protects mice from fatal mers-cov infection. MBio 2020. 11(2):20.
- UGA among top universities fighting COVID-19; [cited 2020 May 25]. Available from: https://news.uga.edu/uga-ranked-among-top-universities-fighting-covid-19/.
- A New Coronavirus vaccine designed to meet a global demand; [cited 2020 May 25]. Available from: https://www.jefferson.edu/about/news-and-events/2020/4/a-new-coronavirus-vaccine-designed-to-meet-a-global-demand.html.